glp-1 receptor agonists and cancer risk in adults with obesity Glucagon-like peptide 1 risk: the good, the bad and the unknown Glucagon-like peptide-1 receptor agonists compared
Description
[DOI] [PubMed] [Google Scholar] 136.de Heer J, Holst JJ
Association of bariatric surgery with long-term remission of type 2 diabetes and with microvascular and macrovascular complications
Sarcopenic obesity or advanced age ( 65 years)
We saw widespread shortages with Wegovy and Zepbound
However, we know both of these diseases are related to inflammatory markers and the presenters did have data on high-sensitivity C-reactive protein or hsCRP
